Skip to main content

Gilead Sciences, Inc.

corporate_fare Company Profile

Gilead Sciences, Inc.

GILD·NASDAQ·Life Sciences·CIK 0000882095

Gilead Sciences, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering innovative medicines to prevent and treat life-threatening diseases such as HIV, viral hepatitis, COVID-19, and cancer. The company operates in more than 35 countries worldwide, with its headquarters in Foster City, California. In 2025, Gilead's commercial portfolio included over 25 therapies. Key products with approved indications in the U.S. include: In HIV, Biktarvy® is a once-daily oral single-tablet regimen for HIV-1 infection, combining bictegravir, emtricitabine (FTC), and tenofovir alafenamide (TAF). Descovy® is an oral formulation used with other antiretroviral agents for HIV-1 infection and is also FDA-approved for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in certain patients. Descovy is a fixed-dose combination of FTC and TAF. Genvoya® is a once-daily oral single-tablet regimen for HIV-1 infection, combining elvitegravir, cobicistat, FTC, and TAF. Odefsey® is a once-daily oral formulation for the treatment of HIV-1 infection in certain patients.

Gilead Sciences, Inc. (NASDAQ:GILD) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 47 items for GILD at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Gilead Extends Arcellx Tender to April 24, Finalizing $7.8B Deal with CVR; HIV Drug Coverage Varies
  • Gilead Confirms Binding Deal for Ouro Medicines Acquisition, Commits Half of $1.675B Upfront
  • Gilead Nears Up To $2 Billion Acquisition of Autoimmune Biotech Ouro Medicines
  • Gilead Seeks Shareholder Approval for Equity Plan with 10.9% Potential Dilution and Addresses Shareholder Concerns
  • Gilead Reports Strong 2025 Financial Rebound, Details $7B Arcellx Acquisition & Biktarvy Patent Extension

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$29.44B
Net Income
$8.51B
Diluted EPS
$6.78
Op. Cash Flow
$10.02B
Free Cash Flow
$9.46B
Gross Profit
$23.21B
Operating Income
$10.02B
Cash & Equivalents
$7.56B
Total Debt
$24.94B
Debt / Equity
1.10×
Net Margin
28.9%
Shares Outstanding
1.24B sh
Source: 10-K · filed 2026-02-24 · accession 0000882095-26-000006
$167.58 +0.69% today
52-week range · as of 2026-10-29 $114.02 – $167.58
Market cap
$206.43B
Volume
7.6M (1.2× avg)
3-mo avg 6.4M
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed GILD - Filings & News (Page 3)

GILD
Apr 02, 2026, 4:05 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $139.57
Real-time Price: $167.58 info
Change: +$28.01 (+20%) info
Market Cap: $206.43B info
GILD
Mar 31, 2026, 1:32 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $135.60
Real-time Price: $167.58 info
Change: +$31.98 (+24%) info
Market Cap: $206.43B info
GILD
Mar 23, 2026, 12:37 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $137.43
Real-time Price: $167.58 info
Change: +$30.15 (+22%) info
Market Cap: $206.43B info
GILD
Mar 20, 2026, 4:00 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $137.09
Real-time Price: $167.58 info
Change: +$30.49 (+22%) info
Market Cap: $206.43B info
GILD
Feb 24, 2026, 4:18 PM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $147.64
Real-time Price: $167.58 info
Change: +$19.94 (+14%) info
Market Cap: $206.43B info
GILD
Feb 23, 2026, 6:46 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $149.81
Real-time Price: $167.58 info
Change: +$17.77 (+12%) info
Market Cap: $206.43B info
GILD
Feb 10, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $141.88
Real-time Price: $167.58 info
Change: +$25.70 (+18%) info
Market Cap: $206.43B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets